Currently out of the existing stock ratings of Jessica Fye, 131 are a HOLD (35.12%), 213 are a BUY (57.1%), 29 are a SELL (7.77%).

Jessica Fye

Work Performance Price Targets & Ratings Chart

Analyst Jessica Fye, currently employed at JPMORGAN, carries an average stock price target met ratio of 74.43% that have a potential upside of 28.12% achieved within 216 days.

Jessica Fye’s has documented 714 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Energy, Industrials, Technology sectors.

Most recent stock forecast was given on MRNA, Moderna at 21-Aug-2026.

Wall Street Analyst Jessica Fye

Analyst best performing recommendations are on APRE (APREA THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 5/3/2018. The price target of $41 was fulfilled within 1 day with a profit of $4.07 (11.02%) receiving and performance score of 110.21.

Average potential price target upside

of $90.33 (23.05%) on MRSN (MERSANA THERAPEUTICS).
of $193.05 (12.51%) on NKTR (NEKTAR THERAPEUTICS).
of $52.91 (40.76%) on JAZZ (JAZZ PHARMACEUTICALS PLC).

AMRN Amarin PLC ARNA Arena Pharmaceuticals ASND Ascendis Pharma AS BCRX BioCryst Pharmaceuticals CARA Cara Therapeutic CRNX Crinetics Pharmaceuticals DNLI Denali Therapeutics EBS Emergent Biosolutions ESPR Esperion Therapeutics HALO Halozyme Therapeutics IMGN ImmunoGen ITCI Intracellular Th JAZZ Jazz Pharmaceuticals PLC LABP Landos Biopharma MGTA Magenta Therapeutics NKTR Nektar Therapeutics STOK Stoke Therapeutics TCDA Tricida UTHR United Therapeutics IONS Ionis Pharmaceuticals KLDO Kaleido Biosciences LXRX Lexicon Pharmaceuticals RDUS Schnitzer Steel Industries APTX Aptinyx MIRM Mirum Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC LVTX LAVA Therapeutics NV ALNY Alnylam Pharmaceuticals AMAG AMAG Pharmaceuticals APRE Aprea Therapeutics AXLA Axcella Health BNTX BioNTech SE CERE Cerevel Therapeutics Holdings IMCR Immunocore Holdings Ltd INCY yte LEGN Legend Biotech Corp MDCO The Medicines Company MRNA Moderna MRSN Mersana Therapeutics NVCR Novocure Ltd RUBY Rubius Therapeutics SGEN Seagen ALKS Alkermes Plc BMRN Biomarin Pharmaceutical INSM Insmed VRTX Vertex Pharmaceuticals BGNE BeiGene Ltd RYZB RayzeBio, Common Stock ZYME Zymeworks Common Stock AM Antero Midstream Partners LP AR Antero Resources Corp CAR Avis Budget Group IT Gartner MD Mednax MG Mistras Group

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Roanna Ruiz (LEERINK)

Hold Since 19-Oct-2022

$12

$-1.63 (-11.96%)

$800

10 months 11 days ago
(30-Oct-2025)

2/4 (50%)

$-4.4 (-26.83%)

1055

Louise Chen (CANTOR FITZGERALD)

Buy Since 16-Apr-2021

2 years 2 months 21 days ago
(20-Jun-2024)

12/26 (46.15%)

$-53.8 (-84.33%)

1398

Jessica Fye (JPMORGAN)

Sell Since 06-May-2022

2 years 9 months 21 days ago
(20-Nov-2023)

0/2 (0%)

$1519.2 (1880.20%)

Michael Yee (JEFFERIES)

Buy Since 25-Oct-2023

$20

$5.52 (38.12%)

2 years 10 months 16 days ago
(25-Oct-2023)

1/17 (5.88%)

$5.8 (40.85%)

Carl Byrnes (NORTHLAND CAPITAL MARKETS)

Hold Since 19-Jul-2023

$25

$10.52 (72.65%)

3 years 1 months 22 days ago
(19-Jul-2023)

1/2 (50%)

$3.4 (15.74%)

175

Show more analysts

Please expand the browser size to see the chart

Which stock is Jessica Fye most bullish on?

Potential upside of $199.39 has been obtained for UTHR (UNITED THERAPEUTICS)

Which stock is Jessica Fye most reserved on?

Potential downside of -$68.55 has been obtained for MRNA (MODERNA)

What Year was the first public recommendation made by Jessica Fye?

On 2012